These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23652215)

  • 1. Clinical impact of early brain atrophy in clinically isolated syndromes.
    Pérez-Miralles F; Sastre-Garriga J; Tintoré M; Arrambide G; Nos C; Perkal H; Río J; Edo MC; Horga A; Castilló J; Auger C; Huerga E; Rovira A; Montalban X
    Mult Scler; 2013 Dec; 19(14):1878-86. PubMed ID: 23652215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.
    Pichler A; Khalil M; Langkammer C; Pinter D; Bachmaier G; Ropele S; Fuchs S; Enzinger C; Fazekas F
    Mult Scler; 2016 Mar; 22(3):340-6. PubMed ID: 26163072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
    Vidal-Jordana A; Sastre-Garriga J; Pérez-Miralles F; Tur C; Tintoré M; Horga A; Auger C; Río J; Nos C; Edo MC; Arévalo MJ; Castilló J; Rovira A; Montalban X
    Mult Scler; 2013 Aug; 19(9):1175-81. PubMed ID: 23319072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.
    De Stefano N; Giorgio A; Battaglini M; Rovaris M; Sormani MP; Barkhof F; Korteweg T; Enzinger C; Fazekas F; Calabrese M; Dinacci D; Tedeschi G; Gass A; Montalban X; Rovira A; Thompson A; Comi G; Miller DH; Filippi M
    Neurology; 2010 Jun; 74(23):1868-76. PubMed ID: 20530323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis.
    Sastre-Garriga J; Arévalo MJ; Renom M; Alonso J; González I; Galán I; Montalban X; Rovira A
    J Neurol Sci; 2009 Jul; 282(1-2):120-4. PubMed ID: 19157420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis.
    Young KL; Brandt AU; Petzold A; Reitz LY; Lintze F; Paul F; Martin R; Schippling S
    Eur J Neurol; 2013 May; 20(5):803-11. PubMed ID: 23369013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.
    Vidal-Jordana A; Sastre-Garriga J; Pareto D; Tur C; Arrambide G; Otero-Romero S; Huerga E; Mitjana R; Auger C; Tintoré M; Rovira A; Montalban X
    Mult Scler; 2018 May; 24(6):721-727. PubMed ID: 28445084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis.
    Tavazzi E; Dwyer MG; Weinstock-Guttman B; Lema J; Bastianello S; Bergamaschi R; Cosi V; Benedict RH; Munschauer FE; Zivadinov R
    Neuroimage; 2007 Jul; 36(3):746-54. PubMed ID: 17498974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    Hagström IT; Schneider R; Bellenberg B; Salmen A; Weiler F; Köster O; Gold R; Lukas C
    J Neurol; 2017 Jul; 264(7):1402-1412. PubMed ID: 28600596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
    Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.
    Sombekke MH; Wattjes MP; Balk LJ; Nielsen JM; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
    Neurology; 2013 Jan; 80(1):69-75. PubMed ID: 23243070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
    Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes.
    Villar LM; Espiño M; Roldán E; Marín N; Costa-Frossard L; Muriel A; Alvarez-Cermeño JC
    Mult Scler; 2011 Jun; 17(6):690-4. PubMed ID: 21436320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal associations between brain structural changes and fatigue in early MS.
    Nourbakhsh B; Azevedo C; Nunan-Saah J; Maghzi AH; Spain R; Pelletier D; Waubant E
    Mult Scler Relat Disord; 2016 Jan; 5():29-33. PubMed ID: 26856940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical isolated syndrome: a 3-year follow-up study in China.
    Liu Y; Duan Y; Yu C; Qin W; Chen H; Dong H; Ye J; Butzkueven H; Li K
    Clin Neurol Neurosurg; 2011 Oct; 113(8):658-60. PubMed ID: 21680087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
    Magraner M; Coret F; Casanova B
    Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.